IBIS V8Tyrer-Cuzick Risk Interpretation

Calculated Model Outputs

10-Year Breast Cancer Risk

Percent

Lifetime Breast Cancer Risk

Percent

Clinical pearl

The 20% lifetime risk threshold is a key criterion for the American Cancer Society (ACS) recommendation for annual screening Breast MRI in addition to mammography. The 10-year risk is often used to discuss chemoprevention with SERMs or Aromatase Inhibitors.

Risk Profile

22% Lifetime

Management Path

High risk. Candidate for high-risk screening (e.g., annual MRI) and discussion regarding chemoprevention (NCCN/ACS guidelines).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Women without a prior personal history of invasive breast cancer or DCIS.

To estimate the 10-year and lifetime risk of developing breast cancer.

To identify high-risk individuals who qualify for enhanced screening (e.g., breast MRI) or chemoprevention (e.g., Tamoxifen, Anastrozole).

Clinical Pearls

Actionable Thresholds

Risk Level	Threshold	Clinical Action
Average Risk	< 15% Lifetime	Standard screening (mammogram).
Moderate Risk	15% - 19% Lifetime	Consider enhanced surveillance.
High Risk	≥ 20% Lifetime	Annual Breast MRI + Mammogram; discuss chemoprevention.

Tyrer-Cuzick vs. Gail Model

The Gail model is often criticized for its limited family history (only first-degree relatives). Tyrer-Cuzick is preferred for women with paternal family history or affected second-degree relatives, as it captures the underlying genetic risk more robustly.

Last Comprehensive Review: 2026

IBIS V8Tyrer-Cuzick Risk Interpretation

Calculated Model Outputs

10-Year Breast Cancer Risk

Percent

Lifetime Breast Cancer Risk

Percent

Clinical pearl

Risk Profile

22% Lifetime

Management Path

High risk. Candidate for high-risk screening (e.g., annual MRI) and discussion regarding chemoprevention (NCCN/ACS guidelines).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Women without a prior personal history of invasive breast cancer or DCIS.

To estimate the 10-year and lifetime risk of developing breast cancer.

To identify high-risk individuals who qualify for enhanced screening (e.g., breast MRI) or chemoprevention (e.g., Tamoxifen, Anastrozole).

Clinical Pearls

Actionable Thresholds

Risk Level	Threshold	Clinical Action
Average Risk	< 15% Lifetime	Standard screening (mammogram).
Moderate Risk	15% - 19% Lifetime	Consider enhanced surveillance.
High Risk	≥ 20% Lifetime	Annual Breast MRI + Mammogram; discuss chemoprevention.

Tyrer-Cuzick vs. Gail Model

Last Comprehensive Review: 2026

Tyrer-Cuzick (IBIS v8)

Calculated Model Outputs

22% Lifetime

When to Use

When to Use

How it Works

The Integrated Risk Factors

Mathematical Foundation

Clinical Pearls

Actionable Thresholds

Tyrer-Cuzick vs. Gail Model

The Evidence

Key Reference

A breast cancer prediction model incorporating familial and personal risk factors

Related Tools

Recent Journal Updates

Tyrer-Cuzick (IBIS v8)

Calculated Model Outputs

22% Lifetime

When to Use

When to Use

How it Works

The Integrated Risk Factors

Mathematical Foundation

Clinical Pearls

Actionable Thresholds

Tyrer-Cuzick vs. Gail Model

The Evidence

Key Reference

A breast cancer prediction model incorporating familial and personal risk factors

Related Tools

Recent Journal Updates